Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure

View through CrossRef
Objective To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF). Methods 95 cases of the aged patients with CHF were randomised into two groups, valsartan group and valsartan combined carvedilol group. Radioactive immunoassays were used to measure the levels of Ang II, TNFα and IL-6 before treatment and three months after treatment. Results Blood plasma TNFα and IL-6 levels fell down in valsartan group and valsartan combined carvedilol group after treatment (p<0.01). There was no significant difference of Ang II after treatment between the two groups (p>0.05). Conclusions Cardiac function of CHF was improved significantly after treatment of valsartan or valsartan combined carvedilol. Treatment of valsartan combined carvedilol is better than that of valsartan in decrease of blood plasma TNFα and IL-6 levels and improvement of cardiac function.
Title: Effect of valsartan and carvedilol on TNFα, IL-6 and angiotensin α on geriatric chronic heart failure
Description:
Objective To observe the effect of Valsartan and carvedilol on TNFα, IL-6 and angiotensin II (Ang II) in geriatric chronic heart failure (CHF).
Methods 95 cases of the aged patients with CHF were randomised into two groups, valsartan group and valsartan combined carvedilol group.
Radioactive immunoassays were used to measure the levels of Ang II, TNFα and IL-6 before treatment and three months after treatment.
Results Blood plasma TNFα and IL-6 levels fell down in valsartan group and valsartan combined carvedilol group after treatment (p<0.
01).
There was no significant difference of Ang II after treatment between the two groups (p>0.
05).
Conclusions Cardiac function of CHF was improved significantly after treatment of valsartan or valsartan combined carvedilol.
Treatment of valsartan combined carvedilol is better than that of valsartan in decrease of blood plasma TNFα and IL-6 levels and improvement of cardiac function.

Related Results

Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Carvedilol ameliorates experimental atherosclerosis by inhibiting the NLRP3 inflammasome
Abstract Objective: To investigate the protective effect of carvedilol against atherosclerosis by inhibiting the NLRP3 inflammasome. Methods:In vitro experiments, human umb...
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Abstract. Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morb...
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
The dose dependency of the alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol in man.
1. The alpha‐ and beta‐adrenoceptor antagonist activity of carvedilol, a beta‐adrenoceptor antagonist with vasodilating properties, and labetalol were investigated in 10 healthy ma...
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
Effect of Lercanidipine on the Pharmacokinetics‐Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease
AbstractThis study evaluates the carvedilol‐lercanidipine drug interaction, and the influence of chronic kidney disease (CKD) on both drugs. Patients with high blood pressure (8 wi...
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study
Abstract: Nitrosamine contamination of generic valsartan was found in 2018. This study aimed to investigate whether long-term use of valsartan increases cancer risk. Pati...
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Development of angiotensin (1‐7) as an agent to accelerate dermal repair
Angiotensin II has been shown to be a potent agent in the acceleration of wound repair. Angiotensin (1‐7), a fragment of angiotensin II that is not hypertensive, was found to be co...
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Abstract: Despite sacubitril/valsartan being on the market since 2015, clinicians are still determining the best way to initiate therapy to optimize outcomes and minimize...

Back to Top